J

Johnson & Johnson

Makes prescription drugs and medical devices

Field Reimbursement Access Manager Oncology

Full-TimePosted on 10/19/2026Deadline 10/26/26
$102k - $177.1k
Senior
Bachelor's, Master's, MBA
Camden, NJ, USA+2 moreMore locations: Philadelphia, PA, USA | Cherry Hill Township, NJ, USA
In PersonMust reside in the listed territory; travel up to 75% of the time.
Customer Experience & SupportCustomer Education & Training

About the job

Requirements
  • A bachelor's degree is required, preferably in healthcare or business/public administration.
  • At least five years of relevant professional experience is required.
  • Account management and/or reimbursement experience in a provider-office setting, including building customer relationships, is required.
  • Demonstrated expertise in pharmacy and medical or buy-and-bill benefit design, coding, billing, prior authorizations, office operations, and appeals processes is required.
  • Reimbursement or relevant managed-care experience, including revenue cycle, buy-and-bill, prior authorization, coding, and appeals processes, is required.
  • Ability to establish relationships, collaborate, and influence across a matrix organization is required.
  • Ability to navigate challenging access scenarios and identify solutions in a timely and efficient manner is required.
  • Strong written and verbal communication and efficient follow-through are required.
  • Experience working with patient-support hub services is required.
  • A valid U.S. driver's license and a driving record that complies with company standards are required.
  • Permanent residence in the listed territory is required.
  • Extensive knowledge of medication access channels, including pharmacy and medical benefits, buy-and-bill, and assignment of benefit across multiple sites of care, is required.
  • Ability to remain current on and anticipate changes in product coverage, access knowledge, marketplace conditions, and stakeholder practices to deliver approved materials effectively is required.
  • Ability to understand and adapt to the changing healthcare ecosystem to customize resources and messaging for healthcare providers and their staff is required.
  • Ability to execute business in accordance with ethical, legal, and compliance standards and complete required training on time is required.
Responsibilities
  • Educate healthcare providers on reimbursement processes, claims submissions, procedures, and payer coding requirements for core and launch products.
  • Collaborate with field support team members, including sales representatives and key account managers, and serve as the local team's reimbursement expert.
  • Address critical patient access and affordability issues with urgency.
  • Partner with managed-care colleagues to understand current policies and potential future changes.
  • Provide field-based reimbursement and access support, education, and problem-solving in accordance with Field Reimbursement Manager Rules of Engagement.
  • Build trust-based relationships with customers across assigned oncology accounts.
  • Manage territory logistics, routing, and account business planning.
  • Maintain and grow knowledge of national, regional, local, and account market dynamics, including coverage and coding requirements.
  • Grow knowledge of hub and specialty distribution channels to improve support for practices and patients.
  • Collaborate with internal departments, including marketing, sales, medical science, SCG, IBG, HCC, and PECS, and serve as a subject-matter expert on education and insights about access and affordability solutions across Medicare, Medicaid managed care, commercial, and other payer types and plans.
  • Remain current on and anticipate changes in product coverage and access knowledge, marketplace conditions, and stakeholder practices to deliver approved materials effectively.
  • Understand and adapt to changes in the healthcare ecosystem to customize resources and messaging for healthcare providers and their staff.
  • Travel up to 75% of the time.
Desired Qualifications
  • An advanced business degree (MBA) or a public health degree (MPH) is preferred.
  • Oncology disease-state experience is preferred.
  • An advanced degree and/or relevant certifications in prior authorization and/or billing and coding are preferred.
  • Strong market-access acumen related to payer approval processes and business acumen is preferred.
  • Understanding of Medicare, Medicaid, and private-payer initiatives affecting reimbursement of pharmaceutical and biotechnology products is preferred.
  • Technical knowledge and expertise in payer policy, including reimbursement coding, coverage, and payment, is preferred.
  • Competence using Salesforce CRM, Microsoft Word, and Microsoft Excel is preferred.
  • Commitment to learning emerging technologies, such as artificial intelligence, through exploration, iteration, and applying new tools over time is preferred.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.